← Back to Screener
Veradermics, Incorporated (MANE)
Price$74.12
Favorite Metrics
Price vs S&P 500 (4W)30.60%
Market Capitalization$3.01B
All Metrics
Price vs S&P 500 (YTD)111.24%
10-Day Avg Trading Volume0.50M
EPS (Annual)$-2.00
ROI (Annual)-48.79%
Cash / Share (Quarterly)$4.04
ROA (Last FY)-45.86%
Cash Flow / Share (Annual)$-2.04
P/B Ratio20.95x
Net Income / Employee (Annual)$-4
Net Interest Coverage (TTM)-253.69x
EPS Incl Extra (Annual)$-2.00
Current Ratio (Annual)16.66x
Quick Ratio (Quarterly)16.05x
3-Month Avg Trading Volume0.47M
52-Week High$80.50
EPS Excl Extra (Annual)$-2.00
Quick Ratio (Annual)16.05x
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)16.66x
Revenue / Employee (Annual)$0
Cash / Share (Annual)$4.04
ROE (Last FY)-48.79%
EPS Basic Excl Extra (Annual)$-2.00
Total Debt / Equity (Quarterly)0.00x
Revenue / Share (Annual)$0.00
Year-to-Date Return113.25%
5-Day Price Return34.21%
EPS Normalized (Annual)$-2.00
Month-to-Date Return27.47%
EBITD / Share (Annual)$-2.04
LT Debt / Equity (Annual)0.00x
Beta-1.43x
52-Week Low$32.00
Analyst Recommendations
Apr 2026
4.40
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
MANEVeradermics, Incorporated | — | — | — | — | $74.12 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Veradermics Inc is a clinical-stage biopharmaceutical company developing therapeutics for aesthetic and dermatological conditions. The company addresses treatment gaps in high-prevalence skin disorders with novel therapeutic approaches.